William E. Duke - Aug 23, 2023 Form 4 Insider Report for Apexigen, Inc. (APGN)

Signature
/s/ Francis Sarena, by power of attorney
Stock symbol
APGN
Transactions as of
Aug 23, 2023
Transactions value $
-$10,173
Form type
4
Date filed
8/25/2023, 06:42 PM
Previous filing
Jun 23, 2023
Next filing
Sep 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APGN Common Stock Tax liability -$10.2K -26.4K -17.11% $0.39 128K Aug 23, 2023 Direct F1
transaction APGN Common Stock Disposed to Issuer -128K -100% 0 Aug 23, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APGN Employee Stock Option (right to buy) Disposed to Issuer -270K -100% 0 Aug 23, 2023 Common Stock 270K $2.46 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

William E. Duke is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units.
F2 Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), each share of Issuer common stock was exchanged for 0.1725 shares of Pyxis common stock and rounded down to the nearest whole share.
F3 One-fourth of the shares vested on June 6, 2023 and 1/48th of the shares vest monthly thereafter. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 46,547 shares of Pyxis common stock at an exercise price of $14.27 per share.